Screener
Tango Therapeutics TNGX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(45,514) | $(39,876) |
| Adjustments to reconcile net loss to net cash from operating activities: | ||
| Depreciation | 463 | 622 |
| Noncash operating lease expense | 972 | 1,012 |
| Stock-based compensation | 10,797 | 7,255 |
| Accretion on marketable securities | (1,124) | (638) |
| Other, net | 21 | (56) |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's net income?
- Tango Therapeutics (TNGX) reported net income of -$45.51M in Q1 2026.
- How has Tango Therapeutics's net income changed year-over-year?
- Tango Therapeutics's net income decreased by 14.1% year-over-year, from -$39.88M to -$45.51M.
- What is the long-term trend for Tango Therapeutics's net income?
- Over 4 years (2021 to 2025), Tango Therapeutics's net income has grown at a 14.9% compound annual growth rate (CAGR), from -$58.24M to -$101.59M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Tango Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude